1. Academic Validation
  2. Cadonilimab: First Approval

Cadonilimab: First Approval

  • Drugs. 2022 Aug;82(12):1333-1339. doi: 10.1007/s40265-022-01761-9.
Susan J Keam 1
Affiliations

Affiliation

  • 1 Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract

Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical Cancer, lung Cancer, gastric/gastroesophageal junction Cancer, oesophageal squamous cell Cancer, liver Cancer and nasopharyngeal Cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical Cancer (r/mCC) who have progressed on or after platinum-based chemotherapy. This article summarizes the milestones in the development of cadonilimab leading to this first approval for the treatment of patients with r/mCC.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99808
    抗VEGFR2单抗